Physician group sues Trump administration over dietary guidelines process
The suit, brought by a nonprofit that advocates for plant-based diets, claims HHS and the USDA used a “secret panel” of…
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 702 articles · page 17 of 20 · fetched about 1 hour ago
STAT+: Trump expected to pick White House adviser Heidi Overton to lead FDA
Heidi Overton, a doctor and White House adviser, is expected to be President Trump's pick to lead the FDA.
Read at source →
Fauci adviser David Morens pleads guilty to avoiding records requests, conspiracy to defraud government
Morens said he had agreed to work to avoid public disclosures and to use his influence to advance a company's interests.
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
STAT+: Nonprofit health system raked in $1.1 billion this year from stake in medical billing firm
Private equity firms have taken a strong interest in revenue cycle management firms, such as Ensemble.
Read at source →
Trump administration sued over visa time limit that would affect grad students, postdocs
DHS was sued Tuesday over a sweeping policy change that would limit how long foreign students and scholars can remain…
Read at source →
STAT+: The White House declares ‘promises made, promises kept’ on lowering drug prices. Nice try
In its effort to lower drug prices, the White House has declared "promises made, promises kept." That's a narrative…
Read at source →
STAT+: Real-world psilocybin data suggest need for close monitoring
Amylyx reports success in a pivotal trial, biopharma A-listers join a pain-blocking device company board, and more…
Read at source →
STAT+: Leaders of Mass General, Dana-Farber among hospital execs who got big raises in 2024
Top executives of major health systems got substantial raises, even as their hospitals grappled with plenty of…
Read at source →
STAT+: Government workers feel the squeeze on health care
Municipalities are struggling with the cost of health insurance for their workers, and states are facing a major…
Read at source →
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell…
Read at source →
Kindergarten vaccine exemptions are climbing
Doritos as "real" "food," public-sector health care in trouble, and more health news from Morning Rounds
Read at source →
STAT+: Prominent AI startup rolls out virtual cell model in race to speed up science
A prominent AI startup has rolled out a virtual cell model, advancing the race to speed up science.
Read at source →
STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
Lilly was accused of charging “grossly” excessive prices for different insulin products that forced some patients to…
Read at source →
STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
The Trump administration is revising its rebate pilot for the 340B drug discount program, angering hospitals.
Read at source →STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has…
Read at source →
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent…
Read at source →
Federal government could improve infectious disease monitoring, says federal government
The new CDC director nominee moves to the full Senate vote, Medicaid work requirements will not be delayed, and more…
Read at source →
Opinion: We once praised the American Diabetes Association’s courage. How things have changed
“The ADA is no longer what we’d call a profile in courage,” write Adam Marcus and Ivan Oransky of Retraction Watch.
Read at source →
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
“Too often, regulatory tools authorized to speed patient access to breakthrough treatments are being used in ways that…
Read at source →
Opinion: What a recent op-ed got wrong about our Covid study
“The appropriate counter to Covid revisionism is careful, rigorous, and honest assessment of the U.S. response.”
Read at source →
Syphilis spreads while researchers contend with federal constraints and a drug shortage
At the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug…
Read at source →
Capricor’s data clash and a fugitive in the C-suite
Is the FDA taking inconsistent approaches to Duchenne drugs? And how will a new batch of drug executives shake up their…
Read at source →
Key Senate panel backs Trump’s picks for CDC, pandemic preparedness
In win for RFK Jr., Senate committee sends nominations of Erica Schwartz for CDC director and Sean Kaufman for ASPR to…
Read at source →
Judge denies states’ motion to postpone Medicaid work requirement
Federal judge denied 26 states’ request to postpone the implementation of Medicaid work requirements announced in June.
Read at source →
STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels
Unitaid found the rising price of oil could boost the cost of a widely used HIV medicine it reviewed in a detailed…
Read at source →STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
An FDA advisory panel concluded clinical data for a Capricor treatment for Duchenne muscular dystrophy did not provide…
Read at source →
Ebola outbreak nears milestone, while a vaccine remains months away
Medicaid work rules, FTC sues Hims, and more health news from Morning Rounds
Read at source →
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.
Read at source →
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
Patients, advocates, and experts fear the difficulty in documenting a frailty exemption to Medicaid work requirements…
Read at source →Opinion: U.S. dependence on China is a national security risk
“China is overtly seeking to displace U.S. leadership across the innovative biopharmaceutical value chain,” write…
Read at source →
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
“The next 10 years of mycetoma care will determine whether it remains a story of neglect or becomes one of collective…
Read at source →
Is it safe to drink Red Bull and alcohol? Questionable research tied to energy drink giant has shaped policy
Studies tied to Red Bull helped block warning labels about drinking alcohol along with energy drinks. Independent…
Read at source →
NSF testing new Ph.D. model giving trainees academic and industry experience
Students working in fields eligible for NSF funding will be able to participate, including chemistry, engineering, and…
Read at source →
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the…
Read at source →
STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit
The U.S. Federal Trade Commission sued telehealth company Hims & Hers alleging business practices that agency says…
Read at source →
STAT+: End of Medicare drug subsidy gives Democrats new attack line on rising out-of-pocket costs
The White House decision to end a Medicare drug subsidy plays into Democratic arguments ahead of the midterms.
Read at source →